This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ELND-001

Perrigo Company PLC

Drug Names(s): ELND-001

Description: ELND-001 is an oral Alpha-4 beta-1 integrin (VLA-4) inhibitor.

Deal Structure:

Perrigo and Elan
In December 2013, Perrigo and Elan announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion. In connection with the acquisition, Perrigo and Elan have been combined under a new company incorporated in Ireland and have adopted the global name Perrigo Company plc. Shares of Perrigo will trade on the New York Stock Exchange and the Tel Aviv Stock Exchange under the ticker symbol PRGO. The scheme of arrangement to effect Perrigo's acquisition of Elan has taken effect today, and Elan shareholders will receive the consideration to which they are entitled under the scheme of arrangement within 14 days.

Perrigo and Mylan
In April 2015, Mylan announced that Mylan has made a proposal to acquire Perrigo in a cash-and-stock transaction. Under the terms of the non-binding proposal, which was delivered to Perrigo's Chairman on April 6, 2015,...See full deal structure in Biomedtracker


ELND-001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug